Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1422143 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $9.31Day −8.28%Mkt cap $826M1Y +50.3%Off 52W high −25.5%Vol (1Y) 61.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,693 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.5% of sh out |
| Days to cover7.7d |
| 13F net flow (QoQ)−3.72% |
| Top-10 13F concentration57.9% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$71.6M |
| Earnings (TTM)-$294.6M |
| ROE−94.8% |
| Net margin−412.9% |
| ROIC−205.5% |
| Debt / equity0.06× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−10.4% |
| 1Y+50.3% |
| 3Y−6.6% |
| 5Y−50.9% |
| 10Y+135.1% |
| Since incept. (ann.)+1.6% |
Total return through 2026-07-28 · series begins 2015-11-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)61.4% |
| Ann. volatility (3Y)64.2% |
| Sharpe (1Y)0.97 |
| Sharpe (3Y)0.29 |
| Max drawdown (1Y)−39.0% |
| Max drawdown (3Y)−76.5% |
| Beta (3Y vs SPY)1.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 9.6M | $78M | 10.86% | +7.0% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 8.6M | $70M | 9.66% | +0.0% |
| BVF INC/IL | 8.4M | $69M | 9.51% | −2.0% |
| STATE STREET CORP | 4.5M | $37M | 5.08% | −8.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $31M | 4.26% | new |
| ARMISTICE CAPITAL, LLC | 3.7M | $30M | 4.21% | −24.3% |
| Prosight Management, LP | 3.4M | $27M | 3.78% | +32.7% |
| Deep Track Capital, LP | 2.6M | $21M | 2.98% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.83 | — | $18.3M | +29.5% |
| 2025-12-31 | 2026-03-05 | — | — | $17.3M | — |
| 2025-09-30 | 2025-11-04 | −$0.85 | — | $20.8M | — |
| 2025-06-30 | 2025-08-07 | −$0.75 | — | $15.3M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
License And Collaboration Revenue 97% · Product 3%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
